Related Experiment Videos

Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas

Robert G Hart1, Silvina B Tonarelli, Lesly A Pearce

  • 1Department of Medicine, University of Texas Health Science Center, San Antonio, TX 78229-3900, USA. hartr@uthscsa.edu

Stroke
|June 11, 2005
PubMed

Insights

Intracerebral hemorrhages (ICHs) are a rare but serious risk of antithrombotic drugs. Managing blood pressure and anticoagulation intensity can reduce ICH occurrence in patients.

Area of Science:

  • Neurology
  • Cardiology
  • Pharmacology

Background:

  • Antithrombotic therapies are crucial for preventing thrombotic events but carry a risk of intracerebral hemorrhage (ICH).
  • Approximately 7000 ICHs occur annually in the US due to antithrombotic use.
  • This review focuses on ICH in patients on long-term anticoagulation or antiplatelet therapy.

Purpose of the Study:

  • To review the incidence of ICH in patients using antithrombotic therapies.
  • To identify risk factors and predictors of ICH in this patient population.
  • To provide evidence-based recommendations for reducing ICH risk.

Main Methods:

  • Literature review of recent reports on ICH incidence during anticoagulation.
  • Analysis of risk factors including patient age, blood pressure, and medication combinations.
  • Evaluation of the impact of blood pressure control and anticoagulation intensity.

Main Results:

  • ICH rates during oral anticoagulation are reported between 0.3% and 0.6% annually.
  • Key risk factors include advanced age, hypertension, high anticoagulation intensity, and prior cerebral ischemia.
  • Combining antiplatelet agents or using aspirin with clopidogrel increases ICH risk; blood pressure lowering reduces ICH frequency.

Conclusions:

  • ICH is an uncommon yet potentially fatal complication of antithrombotic therapy, especially in patients with prior stroke.
  • Maintaining an international normalized ratio (INR) ≤3.0, controlling hypertension, and avoiding combined aspirin-warfarin therapy can decrease ICH frequency.
Abstract

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...